Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Revolution Medicines, Inc.

Revolution Medicines focuses on developing targeted therapies for cancer treatment. The company is self-described as being 'on target' to outsmart cancer.

Metric
Company Name	Revolution Medicines, Inc.
Symbol	RVMD
MSH ID	COM:REVMED
Market	STOCKS
Sector	Healthcare
Industry	Biotechnology
Country	US
Stage
Employee Count	411
Website	revmed.com
LinkedIn
Founders

Metric
Market Cap	7.01B
Enterprise Value
Monthly Web Traffic	45.68K
Web Traffic Growth	-0.26
Valuation
Raised Capital	323.60M

Metric
Revenue	11.58M
Revenue (LTM)
Revenue (NTM)
Gross Profit	2.27M
EBITDA	-477.88M
Operating Income	-487.19M
Net Income	-436.37M
EPS	-3.86
Diluted EPS	-3.86
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.20
Operating Profit Margin	-42.07
EBITDA Margin	-41.27
Net Profit Margin	-36.85
Return on Equity	-0.35
Return on Assets	-0.20
Return on Capital Employed	-0.25

COM:REVMED

Revolution Medicines

Last Close

56.78

22/11 21:00

Market Cap

7.01B

Beta: -

Volume Today

1.17M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-10.26
P/B Ratio	3.94
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	11.40K
EV Multiple	-11.44

Metric
Days Sales Outstanding	4.31
Days Payables Outstanding
Days Inventory Outstanding	0.00
Operating Cycle	39.53
Cash Conversion Cycle	-1.01K
Asset Turnover	0.01

Metric
Operating Cash Flow	-350.57M
Free Cash Flow	-358.30M
Cash Flow to Debt	-3.99
Operating Cash Flow/Sales	-30.27
Free Cash Flow Yield	-0.06

Metric
Cash & Equivalents	696.15M
Accounts Receivable	3.42M
Inventory
Goodwill	14.61M
Debt to Capitalization	0.05
Debt to Assets	0.06
Current Ratio	9.64
Quick Ratio	18.45

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	1.71
R&D to Revenue	13.02
SG&A to Revenue	2.07